PT  - JOURNAL ARTICLE
AU  - R.E. Stevenson
AU  - J. Liu
AU  - A. Iqbal
AU  - B. DuPont
AU  - N. Sahajpal
AU  - M. Ho
AU  - J.W. Yu
AU  - S.J. Brody
AU  - M. Ganapathi
AU  - A. Rajkovic
AU  - T. Smolarek
AU  - F. Boyar
AU  - P. Bui
AU  - A.M. Dubuc
AU  - R. Kolhe
AU  - B. Levy
TI  - Multisite evaluation and validation of Optical Genome Mapping for prenatal genetic testing
AID  - 10.1101/2022.12.19.22283552
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.12.19.22283552
4099  - http://medrxiv.org/content/early/2022/12/20/2022.12.19.22283552.short
4100  - http://medrxiv.org/content/early/2022/12/20/2022.12.19.22283552.full
AB  - Cytogenetic studies represent a critical component of prenatal genetic testing. Prenatal diagnostic testing of amniotic fluid, chorionic villus sampling, or more rarely, fetal cord blood, is recommended following a positive or unreportable NIPT, maternal serum screen, abnormal ultrasound or increased genetic risk based on family history. While chromosomal microarray is the recommended first-tier prenatal diagnostic test for the detection of sub-microscopic copy number variants, in practice, multiple assays are often assessed, in concert, to achieve a final diagnostic result. The use of multiple methodologies is costly, time consuming, and labor intensive.Optical genome mapping is an emerging technique with application for prenatal diagnosis because of its ability to detect and resolve, in a single assay, all classes of pathogenic cytogenetic aberrations detectable by karyotyping, FISH, and microarray. In an effort to characterize the potential of optical genome mapping as a novel alternative to conventional testing, a multi-site, multi-operator, multi-instrument clinical research study was conducted to demonstrate its analytic validity and clinical utility. In the first phase a total of 200 specimens representing 123 unique cases demonstrated 100% concordance with standard of care methods and 100% reproducibility between sites, operators, and instruments. Analysis and interpretation of cases with incidental findings of potential clinical significance also were performed.Competing Interest StatementNone - JL, AI, BD, NS, MH, JWY, SJB, MG, AR, TS, FB, PB, AMD, BL RES is a consultant of Bionano Genomics, RK has received honoraria, and/or travel funding, and/or research support from Illumina, Asuragen, QIAGEN, Perkin Elmer Inc, Bionano Genomics, Agena, Agendia, PGDx, Thermo Fisher Scientific, Cepheid, and BMS. Funding StatementPartly funded by Bionano Genomics, IncAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB 00007527: University of Rochester Medical Center Office for Human Subject Protection IRB AAAT9083: Columbia University Irving Medical Center, New York, NY, USA IRB 2022 0865: Cincinnati Childrens Hospital Institutional Review Board, Cincinnati, OH, USA IRB 20212956: Bionano Genomics Inc., San Diego, CA, USA IRB 22 37290: University of California San Francisco, San Francisco, CA, USA IRB A #00000150 (HAC IRB # 611298): Medical College of Georgia, Augusta University, Augusta, GA, USAI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesanonymized data may be made available upon request